Skip to main content
mammography

Breast Cancer Research Program

The Breast Cancer Research Program has a strong emphasis on high-impact, collaborative, multi-disciplinary and mechanism-based research encompassing breast epithelial cell and molecular biology, genetics and genomics, immunotherapy, basic science-driven translational and clinical research, innovative clinical trials, and molecular epidemiology. Program members conduct research across a variety of disciplines and research focus areas, including: cellular signaling and molecular biology; breast pathology; genomic profiling; biomedical informatics; medical, surgical, and radiation oncology; clinical trial design; epidemiology; and supportive care studies.

RESEARCH THEMES

The Breast Cancer Program has expertise in and leads clinical trials related to:

Identifying the role of PI3K inhibitors in resistance to antiestrogens in ER+ breast cancer

Molecular sub-classification of triple negative breast cancer and discovery of novel treatment targets

Evaluating non-invasive imaging technologies to predict anti-cancer drug action and treatment response

Studying the role of ERBB3 in mammary gland development, transformation and adaptive resistance

Understanding the role of TGFβ in cancer stem-like behavior and tumor progression

Investigating obesity as a metabolic marker of breast cancer risk in African Americans

Discovering actionable therapy targets in drug-resistant breast tumors after neoadjuvant therapy

Leading innovative clinical trials with targeted therapies and combinations

Meet the Program Members

The Breast Cancer Research Program includes around 30 members from multiple basic science and clinical departments across Vanderbilt University and Medical Center. Ingrid Mayer, M.D., M.S.C.I., and Ben Park, M.D., Ph.D., co-lead the program.


Featured Publications

Program News

December 28, 2020

Pal named to cancer research national leadership posts

Tuya Pal, MD, Ingram Professor of Cancer Research and associate director for Cancer Health Disparities at Vanderbilt-Ingram Cancer Center, has been named to two cancer research leadership posts.
November 12, 2020

New therapeutic target for lung cancer

Continuous activation of cell surface receptors increases signaling that can promote oncogenic transformation. One receptor, EphA2, has been identified as a driver of lung cancer, but its interacting partners are not well characterized.
October 21, 2020

Park named director of Hematology and Oncology at VICC

After serving as interim director since Jan. 1, Ben Ho Park, MD, PhD, Donna S. Hall Professor of Breast Cancer Research at Vanderbilt University Medical Center, has been named director of the Division of Hematology and Oncology.